The HiP™ (High Purity) distinction by BPS Bioscience starts, of course (as the name says), with a high purity level. But that’s not enough. Such pure proteins may aggregate, which is not compatible with binding assays. Thus, the HiP™ label also demands a low level of aggregation, or even none at all.
When researchers need to set up immunotherapy assays, HiP™ proteins deliver what they promise. They are soluble, functional and native proteins, which have passed BPS Biosciences’ rigorous quality control standards to ensure this high grade of quality:
- >90% of purity – monitored by SDS-PAGE and Coomassie blue staining
- <10% of aggregation – controlled by FPLC (Fast Protein Liquid Chromatography)
- Specific activity – revealed by reporter cell-based assays
66 proteins have already earned the HiP™ distinction. They are useful for binding assays and notably to screen inhibitors of a specific binding such as PD-1:PD-L1. For further in vivo studies, you might also be interested in cell-based assays tools such as the PD-1/NFAT reporter Jurkat cell line.
Any questions or comments? If you’d like to know more, leave me a message below, I’ll be pleased to get back to you!
Interested in learning more about tools like this?
Subscribe to thematic newsletters on your favourite research topics.
